Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ: NBTX )

3.300 +0.010 (+0.30%)
Streaming Delayed Price Updated: 12:50 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,363
Open 3.260
Bid (Size) 3.190 (1)
Ask (Size) 3.300 (1)
Prev. Close 3.290
Today's Range 3.260 - 3.300
52wk Range 2.760 - 7.510
Shares Outstanding 34,432,122
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire

Performance

YTD
+13.79%
+13.79%
1 Month
-9.54%
-9.54%
3 Month
+2.80%
+2.80%
6 Month
-33.47%
-33.47%
1 Year
-42.21%
-42.21%

More News

Read More
Earnings Scheduled For April 2, 2025
Via Benzinga
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
From Nanobiotix S.A.
Via GlobeNewswire
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Participate in Multiple Investor Conferences in November
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.